Price:
Rs. 48,000.00
Sample Type: Peripheral Blood
Fasting Not Required
Notes:N8279
Frequently Asked Questions (FAQ's):
What does the LiquiCore 52 Gene Panel include?
It evaluates 52 critical cancer-associated genes to identify actionable mutations, resistance markers, and prognostic variants.
Why is this test important?
It helps guide targeted therapy decisions, monitor disease progression, and detect emerging resistance using a minimally invasive blood sample.
Who should take this test?
Patients with solid tumors, those unable to undergo tissue biopsy, or individuals needing ongoing molecular monitoring may benefit.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses ultra-deep Next Generation Sequencing to detect circulating tumor DNA (ctDNA) with high precision.
What type of sample is required?
A peripheral blood sample is collected in specialized NGS-compatible tubes.
Is any preparation needed?
No fasting or special preparation is required before blood collection.
How quickly are results available?
Metropolis Healthcare typically provides detailed molecular reports within a clinically appropriate timeframe to support treatment decisions.
Can this test help guide treatment choices?
Yes, actionable mutations identified through this panel can help oncologists select targeted therapies and tailor personalized treatment plans